What's Happening?
Velocity Clinical Research has appointed Andrew Reina as Chief Revenue Officer, effective immediately. Reina, formerly of Fortrea, brings extensive experience in driving growth strategies and global business
development. His appointment is seen as a pivotal step in Velocity's evolution, aiming to enhance strategic relationships with multisite clinical research corporations, Sponsors, and CRO partners. Reina will lead the revenue and partnership strategy, focusing on aligning patient recruitment expectations with strategic delivery for biotech and leading pharma companies. His role will involve driving growth through strategic partnerships and aligning business development, marketing, and network operations to deliver consistent revenue performance.
Why It's Important?
Reina's appointment is significant for Velocity Clinical Research as it seeks to strengthen its position as a strategic partner in the clinical research industry. His experience in forging enterprise-level partnerships and optimizing site networks is expected to enhance Velocity's ability to meet the evolving needs of clinical research. This move is crucial as the industry faces growing complexities in clinical trial execution, and Velocity aims to accelerate speed to market and alleviate burdens on sites and patients. The appointment reflects the company's commitment to delivering high-quality data and operational excellence in clinical trials.
What's Next?
Reina will focus on expanding Velocity's strategic partnerships with Sponsors and CROs, aligning business development efforts to drive growth. His leadership is expected to enhance Velocity's ability to deliver superior trial outcomes and meet the needs of biotech and pharma companies. The company will continue to leverage its integrated site network to provide efficient clinical trial solutions across the U.S. and Europe.
Beyond the Headlines
Reina's appointment underscores the importance of strategic leadership in navigating the complexities of clinical research. It highlights the need for integrated site networks to deliver quality and efficiency in clinical trials, and the role of strategic partnerships in driving industry growth.
